Quick Answer
Spyre Therapeutics, Inc. reported Net Income Loss of -$155.20 million for the year ending 2025.
- Spyre Therapeutics, Inc. showed an increase of +25.4% in Net Income Loss from 2024 to 2025.
- This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Spyre Therapeutics, Inc.'s Net Income Loss has declined by 1,400.0%.
- Historical annual values: Fiscal year 2025: -$155.20 million | Fiscal year 2024: -$208.02 million | Fiscal year 2023: -$338.79 million | Fiscal year 2022: -$83.82 million | Fiscal year 2021: -$65.80 million | Fiscal year 2020: -$80.89 million | Fiscal year 2019: -$78.25 million | Fiscal year 2018: -$44.35 million | Fiscal year 2017: -$27.24 million | Fiscal year 2016: -$21.70 million | Fiscal year 2015: -$11.30 million | Fiscal year 2014: -$10.35 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: